OBJECTIVES: To determine the proportion of patients with tumor response, the proportion who survived progression-free for at least 6 months (progression-free survival >or= 6 months), and the frequency and severity of toxicities of patients with recurrent squamous cell carcinoma of the uterine cervix treated with erlotinib. METHODS: This was a multicenter, open-label, single-arm trial evaluating the toxicity and efficacy of oral erlotinib at an initial dosage of 150 mg daily until progressive disease or adverse effects prohibited further therapy. RESULTS: Twenty-eight patients with squamous cell carcinoma were enrolled onto this trial. Twenty-five patients were evaluable. There were no objective responses, with 4 (16%) patients achieving stable disease; only 1 patient had a progression-free survival of 6 months (4%) or more. The 1-sided 90% confidence interval for response was 0.0% to 8.8%. The 2-sided 90% confidence interval for the proportion of patients surviving progression-free for at least 6 months is 0.2% to 17.6%. Erlotinib was well tolerated, with the most common drug-related adverse events being gastrointestinal toxicities, fatigue, and rash. CONCLUSIONS: Erlotinib is inactive as monotherapy in patients with recurrent squamous cell carcinoma of the uterine cervix.
OBJECTIVES: To determine the proportion of patients with tumor response, the proportion who survived progression-free for at least 6 months (progression-free survival >or= 6 months), and the frequency and severity of toxicities of patients with recurrent squamous cell carcinoma of the uterine cervix treated with erlotinib. METHODS: This was a multicenter, open-label, single-arm trial evaluating the toxicity and efficacy of oral erlotinib at an initial dosage of 150 mg daily until progressive disease or adverse effects prohibited further therapy. RESULTS: Twenty-eight patients with squamous cell carcinoma were enrolled onto this trial. Twenty-five patients were evaluable. There were no objective responses, with 4 (16%) patients achieving stable disease; only 1 patient had a progression-free survival of 6 months (4%) or more. The 1-sided 90% confidence interval for response was 0.0% to 8.8%. The 2-sided 90% confidence interval for the proportion of patients surviving progression-free for at least 6 months is 0.2% to 17.6%. Erlotinib was well tolerated, with the most common drug-related adverse events being gastrointestinal toxicities, fatigue, and rash. CONCLUSIONS:Erlotinib is inactive as monotherapy in patients with recurrent squamous cell carcinoma of the uterine cervix.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: R Marzano; G Corrado; R Merola; C Sbiroli; F Guadagni; E Vizza; F Del Nonno; M Carosi; M Galati M; I Sperduti; A M Cianciulli Journal: Eur J Cancer Date: 2004-07 Impact factor: 9.162
Authors: Bradley J Monk; Michael W Sill; Robert A Burger; Heidi J Gray; Thomas E Buekers; Lynda D Roman Journal: J Clin Oncol Date: 2009-01-12 Impact factor: 44.544
Authors: Craig D Woodworth; Laura P Diefendorf; David F Jette; Abdulmajid Mohammed; Michael A Moses; Sylvia A Searleman; Dan A Stevens; Katelynn M Wilton; Sumona Mondal Journal: Virology Date: 2011-10-05 Impact factor: 3.616
Authors: Warner K Huh; William E Brady; Paula M Fracasso; Don S Dizon; Matthew A Powell; Bradley J Monk; Charles A Leath; Lisa M Landrum; Edward J Tanner; Erin K Crane; Stefanie Ueda; Michael T McHale; Carol Aghajanian Journal: Gynecol Oncol Date: 2020-07-06 Impact factor: 5.482
Authors: John K Chan; Wei Deng; Robert V Higgins; Krishnansu S Tewari; Albert J Bonebrake; Michael Hicks; Stephanie Gaillard; Pedro T Ramirez; Weldon Chafe; Bradley J Monk; Carol Aghajanian Journal: Gynecol Oncol Date: 2017-07-18 Impact factor: 5.482